BOULDER, Colo., Oct. 23 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH), is presenting data today at the AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This year's conference is being held October 22-26, 2007 at the Moscone Convention Center, San Francisco, Calif.
In a poster session, Tapestry investigators will be discussing data from preclinical studies of TPI 287, the company's proprietary next-generation taxane for the treatment of multiple cancer indications, on Tuesday, October 23, 2007 from 12:30 - 2:30 PM Pacific Time in the Drug Resistance Session A:
Poster #192: "TPI 287, A Next Generation Taxane Derivative, Functionally
Modulates MDR1 P-glycoprotein Drug Transport Pump and is Active in
Resistant Tumor Cells"
The poster outlines a number of different assays confirming Tapestry's observation that its lead drug candidate TPI 287 is less sensitive in a variety of cancer cell lines to MDR1 mediated efflux than other approved taxanes. MDR1 mediated drug efflux may be a primary cause of resistance to chemotherapy with taxanes.
Additionally, TPI 287 is retained at higher levels in MDR1 expressing cell lines than either paclitaxel or IDN 5109, another taxane in development purported to be active in MDR1 expressing tumors. In addition, TPI 287 has demonstrated tumor growth inhibition when delivered orally in subcutaneous mouse xenograft models of both pancreatic cancer and glioblastoma multiforme (GBM). Tapestry has Phase 2 studies underway for TPI 287 in pancreatic and prostate cancer. The Company plans to evaluate TPI 287 in a Phase 2 study in GBM. A copy of the poster is available on Tapestry's website at http://www.tapestrypharma.com.
About TPI 287
TPI 287, a proprietary next-generation taxane, is Tapestry's lead clinical compound. This compound was designed to overcome multiple drug resistance in solid tumors that are innately resistant to taxane therapy or have become resistant to taxanes following exposure to chemotherapy drugs. In preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and has shown inhibition of human tumor growth in certain animal xenograft models when tested against standard comparative agents. The in vitro activity was seen across multiple cell lines including cell lines known to be sensitive to taxanes as well as cell lines known to be resistant to taxanes. Taxane sensitive cell lines in which TPI 287 has shown activity include cell lines derived from breast cancer, uterine cancer and non-small cell lung cancer. Taxane resistant cell lines in which TPI 287 has shown activity include cell lines derived from breast cancer, colon cancer and prostate cancer.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer.
For more information about Tapestry and its technologies, visit Tapestry's website at http://www.tapestrypharma.com.
Statements in this press release that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Forward- looking statements can be identified by the use of words such as "opportunities," "trends," "potential," "estimates," "may," "will," "should," "anticipates," "expects," "hopes," "plans" or comparable terminology or by discussions of strategy. Such forward-looking statements include the statements relating to the activity of TPI 287 in resistant tumors and the progress of TPI 287 in clinical trials. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward- looking statements. Such risks, uncertainties and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, and June 27, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.
Contact: Tapestry Pharmaceuticals, Inc.
Senior Vice President, Chief Financial Officer
Investor: Laura Perry
Stern Investor Relations, Inc.
Media: Lloyd Benson/Dana Conti
|SOURCE Tapestry Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved